Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline-Reference-Cited by-同舟云学术

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Published:2014-07-24 Issue:4 Volume:124 Page:511-518
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Branford Susan¹²³⁴,Yeung David T.¹²⁵⁶,Parker Wendy T.¹³,Roberts Nicola D.¹,Purins Leanne¹,Braley Jodi A.¹,Altamura Haley K.¹,Yeoman Alexandra L.¹,Georgievski Jasmina¹,Jamison Bronte A.¹,Phillis Stuart¹,Donaldson Zoe¹,Leong Mary¹,Fletcher Linda¹,Seymour John F.⁶⁷⁸,Grigg Andrew P.⁶⁸⁹,Ross David M.²⁵⁶¹⁰,Hughes Timothy P.²⁵⁶¹¹

Affiliation:

1. Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;

2. School of Medicine, and

3. School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia;

4. School of Pharmacy and Medical Science, University of South Adelaide, Adelaide, Australia;

5. Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;

6. Australasian Leukaemia and Lymphoma Group, East Melbourne, Australia;

7. Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia;

8. University of Melbourne, Parkville, Australia;

9. Department of Haematology, Austin Hospital, Melbourne, Australia;

10. Department of Haematology, Flinders University and Medical Centre, Bedford Park, Australia; and

11. Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

Abstract

Key Points Among patients with >10% BCR-ABL1, at 3 months, the poorest-risk group can be distinguished by the rate of BCR-ABL1 decline from baseline. Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow-up.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/4/511/1381999/511.pdf

Reference52 articles.

1. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.;Wang;Br J Haematol,2003

2. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.;Marin;J Clin Oncol,2012

3. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).;Hanfstein;Leukemia,2012

4. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.;Branford;J Clin Oncol,2012

5. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.;Marin;Blood,2012

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: ELEGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI IN THE EXPERIENCE OF THE GIMEMA LABNET CML NATIONAL NETWORK;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression;Biomedicines;2024-08-21

3. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02

4. Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population;Indian Journal of Hematology and Blood Transfusion;2024-06-21

5. CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib;Blood Neoplasia;2024-06